Core Viewpoint - The National Medical Products Administration (NMPA) has approved Chengdu Huasheng Technology Group Co., Ltd.'s Sanqi Tongshu Capsules as the first secondary protected traditional Chinese medicine variety, with a protection period of seven years starting from the announcement date [1][2]. Product Information - Product Name: Sanqi Tongshu Capsules - Dosage Form: Capsule - Specification: 0.2g per capsule - Indications: The product is indicated for promoting blood circulation, alleviating blood stasis, improving cerebral infarction and ischemic dysfunction, restoring ischemic brain metabolism abnormalities, preventing platelet aggregation, and improving microcirculation, primarily used for cerebrovascular embolic diseases such as stroke and hemiplegia [1][3]. Product Overview - Sanqi Tongshu Capsules are derived from the active components of the Sanqi herb, specifically the saponins, and are recognized as a new generation of Sanqi preparations. The product has multiple effects, including preventing thrombosis and promoting nerve function recovery, and has been included in various clinical guidelines for the treatment of cerebrovascular diseases. The product has received several awards for its technological advancements and its active ingredient has been recognized in international pharmacopoeias [3]. Impact on the Company - The approval of Sanqi Tongshu Capsules as a secondary protected variety enhances market protection and is expected to improve the product's core competitiveness, positively impacting the company's operations. However, the short-term impact on the company's financial performance is expected to be limited due to uncertainties in the pharmaceutical industry and market environment [4].